Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis

References

• Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015 Oct;74(10):1799–1807.
   PubMed Web of Science ®Google Scholar
• Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013 Dec;72(12):1905–1913.
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Gossec L. When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations. Ann N Y Acad Sci. 2014 May;1318:32–40.
   PubMed Web of Science ®Google Scholar
• Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010 Jun;69(6):1010–1014.
   PubMed Web of Science ®Google Scholar
• Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007 Dec;66(12):1560–1567.
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010 Nov;69(11):1913–1919.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492–509.
   PubMed Web of Science ®Google Scholar
• Caporali R, Todoerti M, Scire CA, et al. Oral low-dose glucocorticoids should be included in any recommendation for the use of non-biologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. Neuroimmunomodulation. 2015;22(1–2):104–111.
   PubMed Web of Science ®Google Scholar
• Bijlsma JW, Jacobs JW, Buttgereit F. Glucocorticoids in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S34–6.
   PubMed Web of Science ®Google Scholar
• Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002 Oct;96(1):23–43.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002 Aug;61(8):718–722.
   PubMed Web of Science ®Google Scholar
• Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008 Oct;4(10):525–533.
   PubMedGoogle Scholar
• Mercieca C, Kirwan JR. The intelligent use of systemic glucocorticoids in rheumatoid arthritis. Expert Rev Clin Immunol. 2014 [2014 01 01];10(1):143–157.
   PubMed Web of Science ®Google Scholar
• Stahn C, Lowenberg M, Hommes DW, et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007 Sep 15;275(1–2):71–78.
   PubMed Web of Science ®Google Scholar
• Jiang CL, Liu L, Li Z, et al. The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms. Steroids. 2015 Oct;102:27–31.
   PubMed Web of Science ®Google Scholar
• Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012 Mar 6;156(5):329–339.
   PubMed Web of Science ®Google Scholar
• Pincus T, Cutolo M. Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis. Neuroimmunomodulation. 2015;22(1–2):46–50.
   PubMed Web of Science ®Google Scholar
• van Everdingen AA, Jacobs JW, Siewertsz van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002 Jan 1;136(1):1–12.
   PubMed Web of Science ®Google Scholar
• Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 Nov;52(11):3371–3380.
   PubMed Web of Science ®Google Scholar
• Ethgen O, De Lemos Esteves F, Bruyere O, et al. What do we know about the safety of corticosteroids in rheumatoid arthritis? Curr Med Res Opin. 2013 Sep;29(9):1147–1160.
   PubMed Web of Science ®Google Scholar
• Johannesdottir SA, Horvath-Puho E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 2013 May 13;173(9):743–752.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Wells AF. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Rheumatology (Oxford). 2014 Oct;53(10):1742–1751.
   PubMed Web of Science ®Google Scholar
• Mazzantini M, Torre C, Miccoli M, et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol. 2012 Mar;39(3):552–557.
   PubMed Web of Science ®Google Scholar
• McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008 Mar;20(2):131–137.
   PubMed Web of Science ®Google Scholar
• Rau R. Glucocorticoid treatment in rheumatoid arthritis. Expert Opin Pharmacother. 2014 Aug;15(11):1575–1583.
   PubMed Web of Science ®Google Scholar
• Saag KG. Short-term and long-term safety of glucocorticoids in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2012;70(Suppl 1):21–25.
   PubMedGoogle Scholar
• Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009 Feb 18;301(7):737–744.
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2010 Jun;69(6):1015–1021.
   PubMed Web of Science ®Google Scholar
• Lin CW, Nakane M, Stashko M, et al. Trans-activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y 1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers. Mol Pharmacol. 2002 Aug;62(2):297–303.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Spies CM, Bijlsma JW. Novel glucocorticoids: where are we now and where do we want to go? Clin Exp Rheumatol. 2015 Jul-Aug;33(4Suppl 92):S29–33.
   PubMed Web of Science ®Google Scholar
• Strehl C, Bijlsma JW, De Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016 Jun;75(6):952–957.
   PubMed Web of Science ®Google Scholar
• Hardy R, Rabbitt EH, Filer A, et al. Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis. 2008 Sep;67(9):1204–1210.
   PubMed Web of Science ®Google Scholar
• Nanus DE, Filer AD, Hughes B, et al. TNFalpha regulates cortisol metabolism in vivo in patients with inflammatory arthritis. Ann Rheum Dis. 2015 Feb;74(2):464–469.
   PubMed Web of Science ®Google Scholar
• Kondratov R. Circadian clock and cancer therapy: an unexpected journey. Ann Med. 2014 Jun;46(4):189–190.
   PubMed Web of Science ®Google Scholar
• Durrington HJ, Farrow SN, Loudon AS, et al. The circadian clock and asthma. Thorax. 2014 Jan;69(1):90–92.
   PubMed Web of Science ®Google Scholar
• Shaw E, Tofler GH. Circadian rhythm and cardiovascular disease. Curr Atheroscler Rep. 2009 Jul;11(4):289–295.
   PubMed Web of Science ®Google Scholar
• Spies CM, Cutolo M, Straub RH, et al. Prednisone chronotherapy. Clin Exp Rheumatol. 2011 Sep-Oct;29(5 Suppl 68):S42–5.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension. 2009 Jul;54(1):40–46.
   PubMed Web of Science ®Google Scholar
• Plakogiannis R, Cohen H. Optimal low-density lipoprotein cholesterol lowering – morning versus evening statin administration. Ann Pharmacother. 2007 Jan;41(1):106–110.
   PubMed Web of Science ®Google Scholar
• Arvidson NG, Gudbjornsson B, Larsson A, et al. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997 Jan;56(1):27–31.
   PubMed Web of Science ®Google Scholar
• Arvidson NG, Gudbjornsson B, Elfman L, et al. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis. 1994 Aug;53(8):521–524.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Villaggio B, Otsa K, et al. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease’s symptoms. Autoimmun Rev. 2005 Nov;4(8):497–502.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Straub RH, Buttgereit F. Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann Rheum Dis. 2008 Jul;67(7):905–908.
   PubMed Web of Science ®Google Scholar
• Cutolo M. Chronobiology and the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2012 May;24(3):312–318.
   PubMed Web of Science ®Google Scholar
• Perry MG, Kirwan JR, Jessop DS, et al. Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis. 2009 Jan;68(1):63–68.
   PubMed Web of Science ®Google Scholar
• Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007 Feb;56(2):399–408.
   PubMed Web of Science ®Google Scholar
• Spies CMHP, Maier B, Huscher D, et al. Circadian rhythms of cellular immunity in rheumatoid arthritis. Arthritis Rheum. 2011;63(Suppl 10):373.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008 Jan 19;371(9608):205–214.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010 Jul;69(7):1275–1280.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013 Feb;72(2):204–210.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Iaccarino L, Doria A, et al. Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol. 2013 Jul-Aug;31(4):498–505.
   PubMed Web of Science ®Google Scholar
• Pfeiffer BM, Krenzer S, Dockhorn R, et al. Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis. Rheumatol Int. 2013 Jun;33(6):1447–1454.
   PubMed Web of Science ®Google Scholar
• Alten R, Grahn A, Holt RJ, et al. Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis. RMD Open. 2015;1(1):e000134.
   PubMedGoogle Scholar
• Alten R, Holt R, Grahn A, et al. Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone. Scand J Rheumatol. 2015;44(5):354–358.
   PubMed Web of Science ®Google Scholar
• Krasselt M, Baerwald C. Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis. Drug Des Devel Ther. 2016;10:1047–1058.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013 Jan;65(1):36–48.
   PubMed Web of Science ®Google Scholar
• Ozbakir B, Crielaard BJ, Metselaar JM, et al. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. J Control Release. 2014 Sep;190(190):624–636.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun. 1975 Apr 7;63(3):651–658.
   PubMed Web of Science ®Google Scholar
• Allen TM, Hansen C, Martin F, et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991 Jul 1;1066(1):29–36.
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Bijlsma JW. Rediscovering the therapeutic use of glucocorticoids in rheumatoid arthritis. Curr Opin Rheumatol. 2016 May;28(3):289–296.
   PubMed Web of Science ®Google Scholar
• Heath JR. Nanotechnologies for biomedical science and translational medicine. Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14436–14443.
   PubMed Web of Science ®Google Scholar
• Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, et al. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. 2003 Jul;48(7):2059–2066.
   PubMed Web of Science ®Google Scholar
• Metselaar JM, van den Berg WB, Holthuysen AE, et al. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis. 2004 Apr;63(4):348–353.
   PubMed Web of Science ®Google Scholar
• Ulmansky R, Turjeman K, Baru M, et al. Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J Control Release. 2012 Jun 10;160(2):299–305.
   PubMed Web of Science ®Google Scholar
• Moallem E, Koren E, Ulmansky R, et al. A liposomal steroid nano-drug for treating systemic lupus erythematosus. Lupus. 2016 Oct;25(11):1209–1216.
   PubMed Web of Science ®Google Scholar
• van der Geest T, Metselaar JM, Gerrits D, et al. [(18)]F FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis. J Control Release. 2015 Jul 10;209:20–26.
   PubMed Web of Science ®Google Scholar
• Barrera P, Mulder S, Smetsers AI, et al. Long-circulating liposomal prednisolone versus pulse intramuscular methylprednisolone in patients with active rheumatoid arthritis. Arthritis Rheum. 2008 Dec;58(12):3976–3977.
   Google Scholar
• Vandevyver S, Dejager L, Tuckermann J, et al. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology. 2013 Mar;154(3):993–1007.
   PubMed Web of Science ®Google Scholar
• Ratman D, Vanden Berghe W, Dejager L, et al. How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol Cell Endocrinol. 2013 Nov 5;380(1–2):41–54.
   PubMed Web of Science ®Google Scholar
• Clark AR. Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol. 2007 Sep 15;275(1–2):79–97.
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 1998 May 15;93(4):531–541.
   PubMed Web of Science ®Google Scholar
• Tuckermann JP, Reichardt HM, Arribas R, et al. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol. 1999 Dec 27;147(7):1365–1370.
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Tuckermann JP, Gottlicher M, et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. Embo J. 2001 Dec 17;20(24):7168–7173.
   PubMed Web of Science ®Google Scholar
• Tuckermann JP, Kleiman A, Moriggl R, et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest. 2007 May;117(5):1381–1390.
   PubMed Web of Science ®Google Scholar
• Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol. 2007 Sep 15;275(1–2):98–108.
   PubMed Web of Science ®Google Scholar
• Schacke H, Berger M, Rehwinkel H, et al. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol. 2007 Sep 15;275(1–2):109–117.
   PubMed Web of Science ®Google Scholar
• Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):227–232.
   PubMed Web of Science ®Google Scholar
• Sundahl N, Bridelance J, Libert C, et al. Selective glucocorticoid receptor modulation: new directions with non-steroidal scaffolds. Pharmacol Ther. 2015 Aug;152:28–41.
   PubMed Web of Science ®Google Scholar
• Miner JN, Ardecky B, Benbatoul K, et al. Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244–19249.
   PubMed Web of Science ®Google Scholar
• Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol. 2001 Feb 1;166(3):1975–1982.
   PubMed Web of Science ®Google Scholar
• Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol. 1997 Aug;11(9):1245–1255.
   PubMed Web of Science ®Google Scholar
• Schacke H, Zollner TM, Docke WD, et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009 Oct;158(4):1088–1103.
   PubMed Web of Science ®Google Scholar
• Spinelli SL, Xi X, McMillan DH, et al. Mapracorat, a selective glucocorticoid receptor agonist, upregulates RelB, an anti-inflammatory nuclear factor-kappaB protein, in human ocular cells. Exp Eye Res. 2014;127:290–298.
   PubMed Web of Science ®Google Scholar
• Baiula M, Bedini A, Baldi J, et al. Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy. Drug Des Devel Ther. 2014;8:745–757.
   PubMed Web of Science ®Google Scholar
• Cavet ME, Volhejn S, Harrington KL, et al. Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells. Mol Vis. 2013;19:1515–1525.
   PubMed Web of Science ®Google Scholar
• Baumer W, Rossbach K, Schmidt BH. The selective glucocorticoid receptor agonist mapracorat displays a favourable safety-efficacy ratio for the topical treatment of inflammatory skin diseases in dogs. Vet Dermatol. 2016 Jul 18. doi: 10.1111/vde.12315. [Epub ahead of print] PubMed PMID: 27425245
   Web of Science ®Google Scholar
• Baiula M, Spampinato S. Mapracorat, a novel non-steroidal selective glucocorticoid receptor agonist for the treatment of allergic conjunctivitis. Inflamm Allergy Drug Targets. 2014;13(5):289–298.
   PubMedGoogle Scholar
• Hu X, Du S, Tunca C, et al. The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation. Endocrinology. 2011 Aug;152(8):3123–3134.
   PubMed Web of Science ®Google Scholar
• Conrado DJ, Krishnaswami S, Shoji S, et al. Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose-response analysis. J Pharmacokinet Pharmacodyn. 2016 May 13;43:325–341.
   PubMed Web of Science ®Google Scholar
• Paul-Clark MJ, Mancini L, Del Soldato P, et al. Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1677–1682.
   PubMed Web of Science ®Google Scholar
• Paul-Clark MJ, Roviezzo F, Flower RJ, et al. Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol. 2003 Sep 15;171(6):3245–3252.
   PubMed Web of Science ®Google Scholar
• Mallei A, Aden SA, Bachis A, et al. The nitrosteroid NCX 1015, a prednisolone derivative, improves recovery of function in rats after spinal cord injury. Brain Res. 2005 Nov 16;1062(1–2):16–25.
   PubMed Web of Science ®Google Scholar
• Oliveira MS, De OBE, Zamuner S, et al. Suppressive effects of nitric oxide-releasing prednisolone NCX-1015 on the allergic pleural eosinophil recruitment in rats. Clin Exp Allergy. 2008 Nov;38(11):1830–1837.
   PubMed Web of Science ®Google Scholar
• Cutolo M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD Open. 2016;2(1):e000203.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Smolen JS, Coogan AN, et al. Clocking in: chronobiology in rheumatoid arthritis. Nat Rev Rheumatol. 2015 Jun;11(6):349–356.
   PubMed Web of Science ®Google Scholar